Cencora, Inc.
COR · NYSE
- $321.57
- $62.27B
- Open
- —
- —
- $322.46 - $327.76
- $244.82 - $377.54
- —
- —
- 1.06M
About Cencora, Inc.
Cencora is a healthcare company that distributes pharmaceutical products and provides related services to pharmacies, hospitals, healthcare providers and biopharmaceutical manufacturers. Its business makes money primarily through pharmaceutical distribution, alongside services supporting drug commercialization and specialty products, including oncology-related therapies. The supplied evidence does not provide a segment revenue split or customer mix. Cencora reports $321.3 billion of fiscal 2025 revenue and $1.6 billion of net income, compared with $294.0 billion and $1.5 billion, respectively, in fiscal 2024. Its scale is therefore dominated by high-volume, relatively low-margin distribution activity.
Notable Price Movement
- Aug 3-7$320.462.93%
Cencora fell $13.30, or 4.16%, from $319.58 to $306.28 over the period, extending a decline visible in the supplied daily closes. The stock slipped on July 29, dropped more sharply on July 30, and continued lower through August 4 without a disclosed company-specific announcement or analyst rating action. Trading volume increased to 1.60 million shares on August 3 and 2.45 million on August 4, suggesting heavier positioning ahead of Cencora’s scheduled August 5 fiscal third-quarter report, although the evidence does not establish direction or cause. Pre-earnings coverage emphasized specialty-pharma and oncology strength against pricing, GLP-1, tariff and funding pressures. No broader market context was supplied.
